HC Wainwright Lifts Earnings Estimates for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – HC Wainwright boosted their FY2026 earnings per share estimates for shares of Dyne Therapeutics in a note issued to investors on Tuesday, March 3rd. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($3.05) per share for the year, up from their prior estimate of ($3.17). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($1.68) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $1.28 EPS and FY2030 earnings at $3.24 EPS.

A number of other research firms have also weighed in on DYN. Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $40.00 price target on shares of Dyne Therapeutics in a report on Monday, December 8th. Morgan Stanley reduced their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday. JPMorgan Chase & Co. decreased their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Finally, Robert W. Baird set a $30.00 price objective on Dyne Therapeutics in a report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $36.13.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $14.86 on Friday. The firm’s 50 day moving average is $17.05 and its 200 day moving average is $17.05. The stock has a market capitalization of $2.45 billion, a P/E ratio of -4.20 and a beta of 1.34. Dyne Therapeutics has a 12 month low of $6.36 and a 12 month high of $25.00. The company has a current ratio of 22.25, a quick ratio of 13.47 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Chung Wu Investment Group LLC bought a new stake in Dyne Therapeutics during the third quarter valued at $30,000. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter worth about $51,000. CWM LLC raised its holdings in shares of Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after acquiring an additional 1,900 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $84,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $50 price target and is projecting strong long‑term recovery (FY2030 EPS of $3.24), signaling meaningful upside in the firm’s model beyond the next several years. MarketBeat Report
• Positive Sentiment: HC Wainwright modestly improved its FY2026 estimate (less negative: from ($3.17) to ($3.05)), which slightly reduces short‑term downside in the firm’s forecasts. MarketBeat Report
• Neutral Sentiment: Analysts from both firms largely converged on near‑term quarterly guidance (many quarters forecast around ($0.76) EPS), and the street consensus full‑year loss remains near ($3.44) — this keeps near‑term expectations stable even as individual line‑items shift. MarketBeat Report
• Neutral Sentiment: Short‑interest data reported for early March appears anomalous (shows zero shares / NaN changes), so the print is likely a reporting glitch and not actionable market pressure. MarketBeat Report
• Negative Sentiment: HC Wainwright reduced FY2028 and FY2029 EPS forecasts (FY2028 to ($0.08) from $0.11; FY2029 to $1.28 from $1.56) and nudged FY2027 slightly lower — these downward revisions compress medium‑term earnings visibility and likely weigh on sentiment. MarketBeat Report
• Negative Sentiment: Lifesci Capital trimmed several near‑term quarterly EPS estimates (Q4 2026 to ($0.86) from ($0.85); Q2 2026 to ($0.79) from ($0.77)), modestly increasing expected near‑term losses and adding short‑term pressure. MarketBeat Report

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.